Summary & Overview
HCPCS J2710: Injection of Neostigmine Methylsulfate, up to 0.5 mg
HCPCS Level II code J2710 designates the injectable medication neostigmine methylsulfate, billed for doses up to 0.5 mg. Neostigmine is used clinically to reverse non-depolarizing neuromuscular blockade after anesthesia and in select gastrointestinal or urologic indications; accurate coding ensures medication billing is captured separately from procedural or facility charges. Nationally, this code matters for hospitals, surgical centers, and emergency departments where parenteral reversal agents are used.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise review of how J2710 is used in claims, typical sites of service, and the clinical contexts that commonly generate this line item. Readers will find benchmarks for utilization and reimbursement where available, summaries of payer coverage tendencies, and relevant coding considerations tied to service lines. The report also outlines gaps in publicly available data and highlights areas where payer policies or documentation requirements commonly affect billing for injectable reversal agents.
This summary is written for a national audience of coding professionals, billing managers, and clinical leaders seeking clarity on the billing classification, common clinical uses, and payer landscape for HCPCS Level II code J2710.
Billing Code Overview
HCPCS Level II code J2710 represents an injection of neostigmine methylsulfate, with dosing reported up to 0.5 mg per unit. This code is used to bill for the medication component when neostigmine methylsulfate is administered to reverse neuromuscular blockade or to treat certain forms of acute colonic pseudo-obstruction, depending on clinical context.
-
Service type: Medication injection
-
Typical site of service: Hospital inpatient or outpatient settings, ambulatory surgical centers, and emergency department administrations where parenteral medications are provided
Clinical & Coding Specifications
Clinical Context
A 68-year-old male inpatient with a recent orthopedic surgery develops acute postoperative urinary retention and generalized muscle weakness suspected to be related to residual neuromuscular blockade after a short-acting non-depolarizing neuromuscular blocker. The anesthesia team evaluates the patient in the post-anesthesia care unit (PACU). After confirming the indication with clinical exam and peripheral nerve stimulator showing inadequate twitch response, the anesthesiologist administers a single iv dose of neostigmine methylsulfate (J2710, up to 0.5 mg) with an anticholinergic (e.g., glycopyrrolate) per institutional protocol to reverse residual paralysis. The typical workflow includes evaluation, documentation of indication and neuromuscular monitoring, medication preparation and verification, administration by a credentialed clinician in PACU or operating room, monitoring for cholinergic side effects, and documentation of dose, time, and patient response.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default code with no modifier | Use when no modifier applies and service is billed under usual circumstances |
76 |